Previous small studies have suggested that low-dose dopamine or neseritide can enhance congestive signs of acute heart failure without altering renal function. 360 patients were included within 24 hours of admission for heart failure with a glomerular filtration rate between 15 and 60 ml/min/1.73 m2. The primary endpoint was the improvement in the congestive signs and symptoms and renal function preservation. Of the total, 119 patients were randomized to 72 hours of therapeutic neseritide and 122 patients at 72 hours with dopamine and finally 119 patients were placebo group. Both drugs failed to show benefits in the primary end point and had no impact on mortality at 60 and 180 days.
Conclusion:
In patients with acute heart failure and renal dysfunction, treatment with low doses of dopamine or neseritide had no impact on the improvement of the congestion or the preservation of renal function.
3_horng_chen_slides
Horng H. Chen.
2013-11-18
Original title: Renal Optimization Strategies Evaluation in Acute Heart Failure Trial.
